Google's $32 Billion Wiz Deal Is About Every Cloud, Not Just GCP
Google's buying Wiz for $32B to deliver AI-driven security across AWS, Azure, and GCP. It won't drop multi-cloud support, and it's Google's biggest bet yet on enterprise security.
Google's buying Wiz for $32B to deliver AI-driven security across AWS, Azure, and GCP. It won't drop multi-cloud support, and it's Google's biggest bet yet on enterprise security.
The US Navy began blocking all ships entering or leaving Iranian ports on Monday after weekend negotiations in Pakistan ended without a deal. Oil prices surged past $100 a barrel, Iran declared its armed forces on "maximum combat alert," and a fragile ceasefire hangs by a thread.
Google's Gemma 4 is one of the most capable open-weight coding models available right now — and with Ollama and Claude Code, you can be up and running in under 10 minutes. No API bills. No data leaving your machine. Just a powerful free coding assistant, running locally.
AAP has removed Raghav Chadha as Deputy Leader in the Rajya Sabha, replacing him with MP Ashok Mittal, and has formally blocked him from the party's speaking quota in the House. Senior leaders, including Bhagwant Mann, have accused Chadha of prioritising "soft PR" over core political work. Chadha has denied the allegations, calling the move politically motivated and an attempt to silence him in Parliament. The episode lays bare deepening factional tensions within the party.
Xivu Arath, we hardly knew ye.
"I thought I would be ready to hear something like this, but I guess I'm just not," said popular streamer Datto....
"It gets very hard to tell what’s light, what’s shadow, what’s dark, what’s safe, what’s dangerous."
No taxation, just representation.
Long gone are the days when third party was for player two.
Prime Monster is a smartly satirical take on the antics of British MPs
MMO to the polls.
Supporters worry that a men’s health office created by the Trump administration risks being dismantled by a future Democratic president
Merck-Kelun ADC outperforms Keytruda in trial, a closely watched Parkinson’s drug fails, and more biotech news from The Readout